42
Mainstream framing
L
R
No clear lean
✓ verified
Why this rating?
· 5 signals
▾
Signals flagged in the original
- ›loaded language: 'cancer-causing'
- ›loaded language: 'alarm patients'
- ›framing: headline asserting a conclusion
- ›editorializing: While the word cancer-causing may alarm patients
- ›vague attribution: health officials stress
Duloxetine Capsules Recalled Due to Elevated Cancer-Causing Chemical Levels
Towa Pharmaceutical and Breckenridge Pharmaceutical have recalled approximately 370,000 bottles of duloxetine capsules due to elevated levels of a potentially cancer-causing chemical, N-nitroso-duloxetine. The FDA has classified the recall as Class II, indicating possible temporary health consequences. Patients are advised to consult healthcare providers regarding the recall and potential treatment options.
Companies
Towa Pharmaceutical
Breckenridge Pharmaceutical
Our neutral summary
Towa Pharmaceutical and Breckenridge Pharmaceutical have recalled approximately 370,000 bottles of duloxetine capsules due to elevated levels of a potentially cancer-causing chemical, N-nitroso-duloxetine. The FDA has classified the recall as Class II, indicating possible temporary health consequences. Patients are advised to consult healthcare providers regarding the recall and potential treatment options.
Read the full story at The Daily Beast ↗
The reporting belongs to
The Daily Beast;
we don't reproduce it.